Research Progress of Breast Cancer Organoids and Application Prospect of Traditional Chinese Medicine
Keywords:
Breast cancer, Organoids, Research progress, Traditional Chinese medicine, OutlookAbstract
Breast cancer is a highly heterogeneous malignancy that includes various subtypes differing in genetics, pathology, clinical treatment, and prognosis. The conventional breast cancer cell line research model does not fully align with the actual pathological process of clinical tumor pathogenesis and the characteristics of tumor heterogeneity. Breast cancer organoid, a model based on the 3D cell culture system, reproduces the heterogeneity of the primary tumor while preserving the molecular phenotype and genotype alterations of the patient’s tumor. Consequently, it has been utilized in studies on tumor pathogenesis and anti-tumor drug screening. Currently, traditional Chinese medicine research on breast cancer primarily focuses on cell lines and patient-derived tumor xenografts, while organoid-related research remains relatively scarce. This review briefly introduces the advancement of the breast cancer organoid culture system and its application in life science research, aiming to provide insights for breast cancer-related studies involving traditional Chinese medicine.
References
Siegel RL, Miller KD, Fuchs HE, et al., 2021, Cancer Statistics. CA Cancer Journal for Clinicians, 71(1): 7–33.
Finlay-Schultz J, Jacobsen BM, Riley D, et al., 2020, New Generation Breast Cancer Cell Lines Developed from Patient-Derived Xenografts. Breast Cancer Research, 22(1): 68–80.
Ilina O, Gritsenko PG, Syga S, et al., 2020, Cell-Cell Adhesion and 3D Matrix Confinement Determine Jamming Transitions in Breast Cancer Invasion. National Cell Biology, 22(9): 1103–1115.
Granat LM, Kambhampati O, Klosek S, et al., 2019, The Promises and Challenges of Patient-Derived Tumor Organoids in Drug Development and Precision Oncology. Animal Models and Experimental Medicine, 2(3): 150–161.
Invrea F, Rovito R, Torchiaro E, et al., 2020, Patient-Derived Xenografts (PDXs) as Model Systems for Human Cancer. Current Opinion in Biotechnology, 63: 151–156.
Renzo MF, Corso S, 2020, Patient-Derived Cancer Models. Cancers, 12(12): 3779.
Li M, Belmonte JCI, 2019, Organoids—Preclinical Models of Human Disease. The New England Journal of Medicine, 380(6): 569–579.
Roelofs C, Hollande F, Redvers R, et al., 2019, Breast Tumour Organoids: Promising Models for the Genomic and Functional Characterisation of Breast Cancer. Biochemical Society Transactions, 47(1): 109–117.
Lee GY, Kenny PA, Lee EH, et al., 2007, Three-Dimensional Culture Models of Normal and Malignant Breast Epithelial Cells. Nature Methods, 4(4): 359–365.
Sato T, Vries RG, Snippert HJ, et al., 2009, Single Lgr5 Stem Cells Build Crypt-Villus Structures In Vitro Without a Mesenchymal Niche. Nature, 459(7244): 262–265.
Sato T, Stange DE, Ferrante M, et al., 2011, Long-Term Expansion of Epithelial Organoids from Human Colon, Adenoma, Adenocarcinoma, and Barrett’s Epithelium. Gastroenterology, 141(5): 1762–1772.
Huch M, Boj SF, Clevers H, 2013, Lgr5+ Liver Stem Cells, Hepatic Organoids and Regenerative Medicine. Regenerative Medicine, 8(4): 385–387.
Karthaus WR, Iaquinta PJ, Drost J, et al., 2014, Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures. Cell, 159(1): 163–175.
Bartfeld S, Clevers H, 2015, Organoids as a Model for Infectious Diseases: Culture of Human and Murine Stomach Organoids and Microinjection of Helicobacter pylori. Journal of Visualized Experiments, 1(105): 53359–53357.
Boj SF, Hwang CI, Baker LA, et al., 2015, Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell, 160(1–2): 324–338.
Twigger AJ, Engelbrecht LK, Bach K, et al., 2022, Transcriptional Changes in the Mammary Gland During Lactation Revealed by Single-Cell Sequencing of Cells from Human Milk. Nature Communication, 13(1): 562.
Rosenbluth JM, Schackmann RCJ, Gray GK, et al., 2020, Organoid Cultures from Normal and Cancer-Prone Human Breast Tissues Preserve Complex Epithelial Lineages. Nature Communication, 11: 1711.
Linnemann JR, Miura H, Meixner LK, et al., 2015, Quantification of Regenerative Potential in Primary Human Mammary Epithelial Cells. Development, 142(18): 3239–3251.
Wang H, Xiang D, Liu B, et al., 2019, Inadequate DNA Damage Repair Promotes Mammary Transdifferentiation, Leading to BRCA1 Breast Cancer. Cell, 178(1): 135–151.e19.
Yang LP, Liu BE, Chen HD, et al., 2020, Progress in the Application of Organoids to Breast Cancer Research. Journal of Cellular and Molecular Medicine, 24(10): 5420–5427.
McLachlan E, Shao Q, Wang HL, et al., 2006, Connexins Act as Tumor Suppressors in Three-Dimensional Mammary Cell Organoids by Regulating Differentiation and Angiogenesis. Cancer Research, 66(20): 9886–9894.
Dekkers JF, Whittle JR, Vaillant F, et al., 2020, Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids. Journal of the National Cancer Institute, 112(5): 540–544.
Bhatia S, Kramer M, Russo S, et al., 2022, Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics. Cancer Research, 82(7): 1174–1192.
Curtis C, Shah SP, Chin SF, et al., 2012, The Genomic and Transcriptomic Architecture of 2,000 Breast Tumours Reveals Novel Subgroups. Nature, 486(7403): 346–352.
Koboldt DC, Fulton RS, McLellan MD, et al., 2012, Comprehensive Molecular Portraits of Human Breast Tumours. Nature, 490(7418): 61–70.
Nik-Zainal S, Davies H, Staaf J, et al., 2016, Landscape of Somatic Mutations in 560 Breast Cancer Whole-Genome Sequences. Nature, 534(7605): 47–54.
Shah SP, Roth A, Goya R, et al., 2012, The Clonal and Mutational Evolution Spectrum of Primary Triple-Negative Breast Cancers. Nature, 486(7403): 395–399.
Cheung KJ, Gabrielson E, Werb Z, et al., 2013, Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program. Cell, 155(7): 1639–1651.
Nguyen-Ngoc KV, Cheung KJ, Brenot A, et al., 2012, ECM Microenvironment Regulates Collective Migration and Local Dissemination in Normal and Malignant Mammary Epithelium. Proceedings of the National Academy of Sciences, 109(39): E2595–E2604.
Park S, Brugiolo M, Akerman M, et al., 2019, Differential Functions of Splicing Factors in Mammary Transformation and Breast Cancer Metastasis. Cell Report, 29(9): 2672–2688.
Diermeier SD, Chang KC, Freier SM, et al., 2016, Mammary Tumor-Associated RNAs Impact Tumor Cell Proliferation, Invasion, and Migration. Cell Report, 17(1): 261–274.
Sharick JT, Walsh CM, Sprackling CM, et al., 2020, Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Frontiers of Oncology, 10: 553.
Walsh AJ, Cook RS, Sanders ME, et al., 2014, Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts Drug Response in Breast Cancer. Cancer Research, 74(18): 5184–5194.
Chen P, Zhang X, Ding RB, et al., 2021, Patient-Derived Organoids Can Guide Personalized Therapies for Patients with Advanced Breast Cancer. Advanced Science, 8(22): e2101176.
Nagle PW, Plukker JTM, Muijs CT, et al., 2018, Patient-Derived Tumor Organoids for Prediction of Cancer Treatment Response. Seminars in Cancer Biology, 53: 258–264.
Drost J, Clevers H, 2018, Organoids in Cancer Research. Nature Reviews of Cancer, 18(7): 407–418.
Walsh AJ, Cook RS, Manning HC, et al., 2013, Optical Metabolic Imaging Identifies Glycolytic Levels, Subtypes, and Early-Treatment Response in Breast Cancer. Cancer Research, 73(20): 6164–6174.
Georgakoudi I, Quinn KP, 2012, Optical Imaging Using Endogenous Contrast to Assess Metabolic State. Annual Review of Biomedical Engineering, 14: 351–367.
Chance B, Schoener B, Oshino R, et al., 1979, Oxidation-Reduction Ratio Studies of Mitochondria in Freeze-Trapped Samples. NADH and Flavoprotein Fluorescence Signals. Journal of Biological Chemistry, 254(11): 4764–4771.
Walsh A, Cook RS, Rexer B, et al., 2012, Optical Imaging of Metabolism in HER2 Overexpressing Breast Cancer Cells. Biomedical Optics Express, 3(1): 75–85.
Warburg O, 1956, On the Origin of Cancer Cells. Science, 123(3191): 309–314.
Lakowicz J, 1999, Principles of Fluorescence Spectroscopy, Plenum Publishers, New York, 1–12.
Blacker TS, Mann ZF, Gale JE, et al., 2014, Separating NADH and NADPH Fluorescence in Live Cells and Tissues Using FLIM. Nature Communication, 5: 3936.
Walsh AJ, Cook RS, Skala MC, 2017, Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen. Journal of Nuclear Medicine, 58(9): 1367–1372.
Zhao Y, Butler EB, Tan M, 2013, Targeting Cellular Metabolism to Improve Cancer Therapeutics. Cell Death and Disease, 4(3): e532.
Walsh AJ, Cook RS, Arteaga CL, et al., 2013, Optical Metabolic Imaging of Live Tissue Cultures. SPIE Conference Proceedings, 3(1): 8588–8599.
Li J, Xu HW, Zhang LX, et al., 2019, Malignant Ascites-Derived Organoid (MADO) Cultures for Gastric Cancer in vitro Modelling and Drug Screening. Journal of Cancer Research and Clinical Oncology, 145(11): 2637–2647.
Weeber F, Ooft SN, Dijkstra KK, et al., 2017, Tumor Organoids as a Preclinical Cancer Model for Drug Discovery. Cell Chemical Biology, 24(9): 1092–1100.
Matano M, Date S, Shimokawa M, et al., 2015, Modeling Colorectal Cancer using CRISPR-Cas9-Mediated Engineering of Human Intestinal Organoids. Nature Medicine, 21(3): 256–262.
Goldhammer N, Kim J, Timmermans-Wielenga V, et al., 2019, Characterization of Organoid Cultured Human Breast Cancer. Breast Cancer Research, 21(1): 1–8.
Wang YC, Hui JR, Zhu YP, et al., 2021, New Perspectives on Strategies and Methods for the Modernization of Traditional Chinese Medicine. China Journal of Chinese Materia Medica, 36(11): 6551–6556.
Wang W, Liu L, Xu H, et al., 2020, Exploration of the Connotation and Essential Characteristics of Pharmacology of Chinese Materia Medica. China Journal of Chinese Materia Medica, 35(3): 1072–1075.
Huang J, Yu J, Yang D, et al., 2021, Analysis on the Theoretical Formation and Connotation of Precision Medicine in Traditional Chinese Medicine. China Journal of Chinese Materia Medica, 36(1): 37–40.
Koval A, Pieme CA, Queiroz EF, et al., 2018, Tannins from Syzygium guineense Suppress Wnt Signaling and Proliferation of Wnt-dependent Tumors Through a Direct Effect on Secreted Wnts. Cancer Letters, 435: 110–120.
Phan NLC, Pham KD, Minh PL, et al., 2020, Hopea odorata Extract Can Efficiently Kill Breast Cancer Cells and Cancer Stem-like Cells in Three-dimensional Culture More Than in Monolayer Cell Culture. Advances in Experimental Medicine and Biology, 6(1292): 145–155.
Ye HS, Gao HF, Li H, et al., 2022, Higher Efficacy of Resveratrol Against Advanced Breast Cancer Organoids: A Comparison with that of Clinically Relevant Drugs. Phytotherapy Research, 36(8): 3313–3324.
Zhang Y, Chen J, Mi D, et al., 2023, Discovery of YH677 as a Cancer Stemness Inhibitor That Suppresses Triple-negative Breast Cancer Growth and Metastasis by Regulating the TGFβ Signaling Pathway. Cancer Letters, 560: 216142.
Liu C, Zhang Y, Gao J, et al., 2023, A Highly Potent Small-molecule Antagonist of Exportin-1 Selectively Eliminates CD44+ CD24– Enriched Breast Cancer Stem-like Cells. Drug Resistance Updates, 66: 100903.
Lin X, Chen D, Chu X, et al., 2023, Oxypalmatine Regulates Proliferation and Apoptosis of Breast Cancer Cells by Inhibiting PI3K/AKT Signaling and its Efficacy Against Breast Cancer Organoids. Phytomedicine, 114: 154752.
Shan P, Wang C, Chen H, et al., 2023, Inonotsutriol E from Inonotus obliquus Exhibits Promising Anti-breast Cancer Activity via Regulating the JAK2/STAT3 Signaling Pathway. Bioorganic Chemistry, 139: 106741.
Deng GL, Zhou LS, Wang BL, et al., 2022, Targeting Cathepsin B by Cycloastragenol Enhances Antitumor Immunity of CD8 T Cells via Inhibiting MHC-I Degradation. Journal for Immunotherapy of Cancer, 10(10): e004874.
Xu HC, Jeught KV, Zhou ZL, et al., 2021, Atractylenolide I Enhances Responsiveness to Immune Checkpoint Blockade Therapy by Activating Tumor Antigen Presentation. Journal of Clinical Investigation, 131(10): e146832.
Xu SH, Fan RL, Wang L, et al., 2022, Synthesis and Biological Evaluation of Celastrol Derivatives as Potent Antitumor Agents with STAT3 Inhibition. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1): 236–251.
Fan S, Xiao G, Ni J, et al., 2023, Guanxinning Injection Ameliorates Cardiac Remodeling in HF Mouse and 3D Heart Spheroid Models via p38/FOS/MMP1-Mediated Inhibition of Myocardial Hypertrophy and Fibrosis. Biomedicine & Pharmacotherapy, 5(162): 114642–114630.
Chen G, Bei B, Feng Y, et al., 2019, Glycyrrhetinic Acid Maintains Intestinal Homeostasis via HuR. Frontiers in Pharmacology, 10: 535.
Fan R, Chen H, Lai B, et al., 2022, Celastrol Exerts Anti-Colorectal Cancer Effect via STAT3 Inhibition. Chinese Pharmacological Bulletin, 38(1): 1673–1680.
Dong RS, Zhang BX, Zhang XW, 2022, Liver Organoids: An In Vitro 3D Model for Liver Cancer Study. Cell Bioscience, 12(1): 1–16.
MacKenzie NJ, Nicholls C, Templeton AR, et al., 2022, Modelling the Tumor Immune Microenvironment for Precision Immunotherapy. Clinical and Translational Immunology, 11(6): e1400–e1422.
Yuan B, Zhao XF, Wang X, et al., 2022, Patient-Derived Organoids for Personalized Gallbladder Cancer Modelling and Drug Screening. Clinical and Translational Medicine, 12(1): e678.
Lin Y, Jiang L, He Q, et al., 2022, Progress and Perspective of Organoid Technology in Cancer-Related Translational Medicine. Biomedicine & Pharmacotherapy, 149: 112869.
Ronaldson-Bouchard K, Baldassarri I, Tavakol D N, et al., 2022, Engineering Complexity in Human Tissue Models of Cancer. Advanced Drug Delivery Reviews, 184: 114181.
Luo LX, Ma YC, Zheng YL, et al., 2022, Application Progress of Organoids in Colorectal Cancer. Frontiers in Cell and Developmental Biology, 10: 815067.
Pang MJ, Burclaff JR, Jin R, et al., 2022, Gastric Organoids: Progress and Remaining Challenges. Cellular and Molecular Gastroenterology and Hepatology, 13(1): 19–33.